SCHEMBL345118

SCHEMBL345118

COC(=O)[C@H](CC(=O)Cl)NC(=O)OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KYNU Q16719 1/20 0.60
ALDH1A1 P00352 3/20 0.58
ALOX15 P16050 1/20 0.58
CTSK P43235 5/20 0.54
CTSS P25774 3/20 0.53
CTSL P07711 2/20 0.53
CTSB P07858 2/20 0.53
CASP1 P29466 2/20 0.52
TRPM8 Q7Z2W7 1/20 0.52
CYP3A4 P08684 2/20 0.52
TSHR P16473 1/20 0.52
TACR1 P25103 2/20 0.51
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21409127 1.00 KYNU (0.60) KYNUALDH1A1ALOX15CTSKCTSS
SCHEMBL1198976 1.00 KYNU (0.60) KYNUALDH1A1ALOX15CTSKCTSS
SCHEMBL7419321 0.92 CASP1 (0.54) KYNUALDH1A1ALOX15CTSKCTSS
SCHEMBL7419324 0.92 CASP1 (0.54) KYNUALDH1A1ALOX15CTSKCTSS
SCHEMBL13724740 0.89 CASP1 (0.64) KYNUALDH1A1ALOX15CTSKCASP1
SCHEMBL19695419 0.89 CASP1 (0.64) KYNUALDH1A1ALOX15CTSKCASP1
SCHEMBL1067460 0.89 CASP1 (0.64) KYNUALDH1A1ALOX15CTSKCASP1
SCHEMBL4404720 0.89 PPARA (0.55) ALDH1A1ALOX15CTSKCTSSCTSL
SCHEMBL4404723 0.89 PPARA (0.55) ALDH1A1ALOX15CTSKCTSSCTSL
SCHEMBL345952 0.87 ALDH1A1 (0.63) KYNUALDH1A1ALOX15CTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102014635-B Difluoro-containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2015-12-16 CN disclosed
EP-2520568-B1 Spirocyclic nitriles as inhibitors of protease SANOFI SA (FR) 2015-09-09 EP disclosed
EP-2079683-B1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY INC (US) 2015-01-21 EP disclosed
US-20140221478-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2014-08-07 US disclosed
US-20140221478-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2014-08-07 US disclosed
US-20140221478-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2014-08-07 US disclosed
US-8748649-B2 Di-fluoro containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2014-06-10 US disclosed
US-8748649-B2 Di-fluoro containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2014-06-10 US disclosed
US-8748649-B2 Di-fluoro containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2014-06-10 US disclosed
US-20140018421-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2014-01-16 US disclosed
US-20080214676-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2008-09-04 US disclosed
US-20080214676-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2008-09-04 US disclosed
US-20080214676-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2008-09-04 US disclosed
WO-2008042968-A2 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2008-04-10 WO disclosed
WO-2008042968-A2 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2008-04-10 WO disclosed
WO-2007137738-A1 SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS SANOFI-AVENTIS (DE) 2007-12-06 WO disclosed
US-20060189657-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2006-08-24 US disclosed
EP-1682524-A1 NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS Aventis Pharmaceuticals, Inc. (US) 2006-07-26 EP disclosed
WO-2005040142-A9 NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS AVENTIS PHARMA INC (US) 2005-06-09 WO disclosed
WO-2005040142-A1 NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214676-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSF, CTSZ, CTSS KYNU 1184/4885ALDH1A1 1867/4885ALOX15 2012/4885
US-20140221478-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSF, CTSZ, CTSS KYNU 1184/4885ALDH1A1 1867/4885ALOX15 2012/4885
US-20140018421-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSF, CTSZ, CTSS KYNU 1184/4885ALDH1A1 1867/4885ALOX15 2012/4885
US-20060189657-A1 Novel compounds and compositions as cathepsin inhibitors CTSB, CTSS, CTSK KYNU 3738/4885ALDH1A1 4379/4885ALOX15 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.